Tata Technologies, Sun Pharma & extra: Top stocks on brokers’ radar for July 17, 2025

JP Morgan maintained its underweight score on Tata Technologies with the goal worth minimize to Rs 570 from Rs 580 earlier. Analysts stated the corporate’s April-June numbers had been a combined one with a beat on revenues whereas margins had been missed. They stated deal closures and ramp-ups improved steadily from April to June. They count on the identical to proceed in July-Sept quarter as purchasers see the necessity to restart R&D spends after a interval of pause.Goldman Sachs maintained its purchase score on Ola Electric Mobility and hiked the inventory’s goal worth to Rs 63 from Rs 60 earlier. Analysts stated that the administration gave a flattish steerage for FY26 revenues and 5% auto earnings earlier than curiosity, taxes, depreciation and amortisation (EBITDA) margin. They additionally acknowledged administration’s efforts in making an attempt to pivot the enterprise in direction of optimistic EBITDA and free money circulation breakeven. They count on that the market might have extra visibility on quantity development and market share execution.JM Financial initiated its protection of Kalyan Jewellers with a purchase suggestion with the goal worth at Rs 700. Analysts really feel there’s an enormous unorganised market offering massive development alternatives for the businesses within the sector. They really feel moats constructed earlier by firms will drive future development. Kalyan Jewellers works on an asset-light mode of retailer enlargement.Citigroup maintained its impartial score on HCL Technologies with the goal worth minimize to Rs 1,650 from Rs 1,690 earlier. Analysts stated the tech main’s April-June earnings earlier than curiosity and taxes (EBIT) at about 7% was under expectations. The firm’s deal pipeline is weak and the general quarterly consequence was respectable on income however gentle on margins. Analysts stated they maintained their cautious view on the sector.Morgan Stanley maintained its obese score on Sun Pharmaceuticals with the goal worth at Rs 1,960. Analysts really feel the US launch and settlement for Leqselvi is a optimistic for the corporate. The launch, anticipated within the second half of FY26, occurred earlier, supporting the obese thesis. Project Leqselvi’s anticipated gross sales at $61 million for FY26 and $83 million for FY27.Disclaimer: The opinions, analyses and proposals expressed herein are these of brokerage and don’t replicate the views of The Times of India. Always seek the advice of with a certified funding advisor or monetary planner earlier than making any funding choices.